Drug Profile
YH 24931
Alternative Names: YH-24931Latest Information Update: 17 Jan 2022
Price :
$50
*
At a glance
- Originator Yuhan
- Class Antineoplastics; Immunotherapies; Recombinant proteins
- Mechanism of Action Dendritic cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 17 Jan 2022 Preclinical trials in Cancer in South Korea (unspecified route) (Yuhan pipeline, January 2022)
- 13 Jan 2016 Preclinical trials in Cancer in South Korea (unspecified route)